While Neuralink human trials sign up are now open and anyone that meets the conditions can apply, Elon Musk is still waiting for the FDA approval that will allow his company to start the trials.
Elon Musk announced on Wednesday that a wireless brain chip built by his business Neuralink will begin human clinical testing in six months, despite the company failing to meet prior deadlines. The business is working on brain chip interfaces that it claims will allow crippled people to move and talk again, with Musk adding on Wednesday that it will also aim to restore eyesight. Neuralink, which is based in the San Francisco Bay Area and Austin, Texas, has been performing animal testing in recent years while it seeks FDA clearance to begin human clinical trials.
Neuralink human trials sign up are open but trials are waiting for FDA approval
“We want to be extremely careful and certain that it will work well before putting a device into a human,” Musk said during the device’s long-awaited public update. Musk stressed the pace with which the business is creating its device in a roughly three-hour presentation to an audience of select attendees at Neuralink headquarters. “The progress at first, particularly as it applies to humans, will seem perhaps agonizingly slow, but we are doing all of the things to bring it to scale in parallel,” he continued. “So, in theory, progress should be exponential.”
According to Musk, the first two human uses targeted by the Neuralink device will be restoring eyesight and facilitating muscular movement in those who are unable to do so. “Even if someone has never had vision, ever, like they were born blind, we believe we can still restore vision,” he stated. The event was initially scheduled for October 31, but Musk canceled it just days before with no explanation. More than a year ago, Neuralink presented a monkey with a brain chip that played a computer game by thinking alone.
He hopes to create a chip that will allow the brain to operate complicated electrical equipment, allowing paralyzed persons to regain movement function and treating brain disorders such as Parkinson’s, dementia, and Alzheimer’s. He also mentions combining the brain and artificial intelligence. Neuralink, on the other hand, is going behind schedule. Musk stated in a 2019 presentation that he hoped to obtain regulatory permission by the end of 2020. He then stated that he wanted to begin human trials this year at a conference in late 2021.
Current and former workers claim that Neuralink has routinely missed internal deadlines to get FDA clearance to begin human studies. Musk approached rival Synchron about a potential investment earlier this year after expressing irritation to Neuralink staff over their poor development. Sign-up for Neuralink human trials is presently open, and you can apply if you satisfy the requirements.
Who can apply to Neuralink human trials sign up?
Anyone in the United States who is at least 18 years old and of the legal drinking age in their state, is able to agree, and has quadriplegia, paraplegia, visual loss, hearing loss, and/or the inability to speak is asked to take part in the human trials. Neuralink will inquire about your current and previous medical history, demography, education, employment, and assistive technology.
They will request your permission to provide your medical records in order for you to join the Patient Registry. If you have a legally authorized representative, they will gather their contact information as well so that they may complete the application on your behalf. You can apply to the Neuralink human trials sign up by visiting the link and following the instructions provided on the page.
This new technology can be a game changer for many people with disabilities and illnesses and applying at Neuralink human trials sign up might allow you to take part in it if FDA approves the trials. As most people know, Elon Musk’s only endeavor is not Neuralink, with Elon Musk firing more Twitter employees night before Thanksgiving and Tesla recalls vehicles in the US because of their windows.